权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

UTMB-Novartis Alliance for Pandemic Preparedness

UTMB-诺华流行病防范联盟

基本信息

批准号：
10845855
负责人：
Thierry Diagana
金额：
$ 1884.9万
依托单位：
UNIVERSITY OF TEXAS MED BR GALVESTON
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-05-16 至 2025-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10845855
关键词：
2019-nCoV Academia Air Antiviral Agents Biology COVID-19 COVID-19 assay COVID-19 pandemic Cells Cessation of life Clinical Collaborations Communicable Diseases Communication Complex Coronavirus Data Decision Making Dengue Development Diagnostic Drug Targeting Education Emerging Technologies Ensure Faculty Family Flavivirus Foundations Future Generations Goals Hendra Virus Henipavirus Home Human Humanities Industry Infection Institution Intellectual Property Investments Laboratories Learning Libraries Life Machine Learning Marketing Medical Medicine Membrane Proteins Mentors Middle East Respiratory Syndrome Coronavirus Nipah Virus Nongovernmental Organizations Nucleosides Nucleotides Oral Peptide Hydrolases Pharmaceutical Preparations Pharmacologic Substance Phase I Clinical Trials Phenotype Polymerase Population Density Postdoctoral Fellow Predisposition Private Sector Privatization Probability Process Productivity Protease Inhibitor Quantitative Structure-Activity Relationship RNA-Directed RNA Polymerase Rationalization Research Research Activity Research Project Grants Resistance SARS-CoV-2 inhibitor Seasons Serotyping Spanish flu Technology Texas Training Translational Research Travel United States National Institutes of Health Universities Vaccines Viral Virus biosafety level 4 facility clinical candidate clinical investigation combat drug candidate drug discovery economic cost inhibitor innovation mortality multidisciplinary new technology next generation novel pandemic disease pandemic potential pandemic preparedness prevent pandemics programs public health relevance public-private partnership recruit response role model screening student training success synergism translational impact viral pandemic virology

项目摘要

OVERALL – ABSTRACT Pandemic prevention and preparedness is a major scientific and societal priority that requires sustained and forward looking investments across governmental, non-governmental, academic and private sectors to develop an arsenal of countermeasures against the existential threat of viral pandemics. Combining world-leading BSL3/4 capabilities at University of Texas of Medical Branch (UTMB) and state-of-the art drug discovery technologies at Novartis, the UTMB Novartis Alliance for Pandemic Preparedness (UNAPP), is a unique and innovative partnership that brings together the multi-disciplinary expertise required to deliver high quality antiviral drug candidates. Enabled by world-leading virologists and seasoned drug hunters, UNAPP will aggressively prosecute a portfolio of 5 projects aiming to discover orally available, safe, and effective drugs against coronaviruses, flavivirus and henipavirus, three major classes of viruses with pandemic potential. The projects portfolio combines approaches targeting well validated drug targets, such as the RNA- dependent RNA polymerases and viral proteases, as well as phenotypic screening, which will allow for the discovery of clinical drug candidates and novel targets that will advance our fundamental understanding of the biology of those viruses. Four scientific Cores—Virology, High-Throughput Biology, Drug Discovery and Translational Research Cores—will provide technological and scientific expertise to support Project Teams and implement the scientific strategy toward novel antiviral drugs. The UNAPP will be governed by an Administrative Core which will be co-led by the PIs, Dr. Pei-Yong Shi and Dr. Thierry Diagana, who have a long track-record of successfully working together. Both PIs have led multiple productive collaborations focused on translational impact and combining public, private and non-governmental organizations. The Administrative Core will provide integrated decision making in scientific, operational, financial, intellectual property protection, and communication. In collaboration with all project and Core leaders, as well as with external input from a Scientific Advisory Board and NIH program officers, they will ensure that the projects portfolio leverages the full spectrum of technologies and capabilities residing in all four scientific Cores, capturing synergies across projects through cross-learning and efficient deployment of platforms relevant to multiple viruses. Because of the unique complementarity of the scientific Cores and the remarkable synergies of the project portfolio, we fully expect that the UNAPP will yield exceptional productivity and deliver all the proposed objectives: (1) Deliver 3 IND-ready candidates and 3 Development Candidates, (2) advance antiviral research, and (3) train next-generation drug hunters.

总体-摘要